Please see the eligibility and requirements section prior to creating an application.
LOI due date: April 3, 2017
LOI results: June, 2017
Application due date: September 15, 2017
Results announcement: January, 2018
Anticipated start date: February 1, 2018
Application guides can be found on the EGrAMS documentation for applicants page. See FAQs.
The Impact Grant program is intended to contribute to the scientific idea ‘pipeline’ by supporting significant progression in cancer research programs, from individual investigators or multidisciplinary teams, that are anywhere in the continuum from basic high impact discovery to translational work of direct relevance to the clinic. Impact Grants will accelerate and focus the knowledge gained from scientific findings, in the short or long term, into outcomes that will significantly advance understanding of cancer and improve scientific knowledge, which will result in optimized patient care, improved cancer treatment or reduced cancer burden. Impact Grants are to provide funding to support ideas that promote major advancement in research programs, whether at the fundamental discovery stage (such as studies involving model organisms that demonstrate potential for impact) through to applied research (such as patient or population based proposals). Note that these grants are not intended to support incremental scientific advances and should not be considered a “regular” research grant and are not intended to solely support research infrastructure.
These grants have been created to support large, well-developed programs in cancer research that have the potential to make a significant impact on the burden of disease in patients and populations. Canada’s research community is particularly strong in basic biomedical and translational science, and there has been a recent explosion of new understanding about cell structure and function and the disease process thanks to significant advances in understanding cell signalling, cell biology, genomics, imaging, and many other fields. The goal of the CCS Research Impact Grant program is to provide a mechanism for scientists to adopt innovations and accelerate the application of new knowledge to address problems in cancer research that have the potential for practical application.
CCS welcomes applications for all cancer types. Given the recent merger between the CCS and CBCF, applications in the area of breast cancer research are encouraged in all CCS Research competitions.
View Program goals and scope for more details.
Scientific focus of the program
This grant program is primarily designed to support the biomedical, translational and clinical research communities addressing scientific questions that will reduce cancer mortality rates. However, applications from all areas and disciplines of cancer research including multidisciplinary applications will be considered eligible for funding and will be evaluated based on a common set of criteria. Applicants are invited to submit proposals for studies that explicitly address the Society’s strategic priorities to reduce cancer incidence, reduce cancer mortality, and improve the quality of life for Canadians living with and beyond cancer.
There is one competition per year. It is anticipated that up to 5 grants will be awarded each competition.
Budgets awarded will not exceed $250,000 per year, to a maximum of $1,250,000 per grant. The grant term is up to 5 years. Grants will be renewable.
Funding will be provided to support the direct costs of research, including supplies, expenses, wages and equipment associated with the proposed work. Indirect costs will not be considered eligible expenses. Equipment requests of up to $125,000 can be included within the proposed budget.
There will be a two stage application and review process. Applicants will be required to submit a letter of intent (LOI) and selected applicants will be invited to submit a full application. One or more multidisciplinary peer review committee(s) will be assembled to review the LOIs and full applications. Peer review committee(s) will consist of scientific experts with broad expertise, along with community representatives to provide patient/survivor/caregiver perspectives.
The review criteria will include, but not be limited to, five assessment categories: Impact, Research Strategy, Investigator(s), Environment, and Cancer Relevance. Given the scope of this competition, significant emphasis will be placed on the impact statement. Applicants should note that the LOI review will result in significant triage; only the strongest LOIs will be invited for full proposals.
- potential to address an important problem or a critical barrier to progress in the field
- potential of the project to make a significant advancement in our understanding of cancer
- potential that scientific knowledge and/or clinical practice can be significantly improved
- potential to deliver tangible benefits in the short or long term to patients or populations, such as new risk reduction strategies, early detection, screening or treatment paradigms, or better outcomes for cancer survivors
- scientific merit and convincing rationale that considers critical review and analysis of preliminary data and/or published literature, as appropriate
- identification of potential problems and how they will be addressed, including alternative approaches
- appropriateness of the term and amount of support requested
- appropriate leadership
- qualifications and appropriate expertise of the investigator(s)
- if project is collaborative or multidisciplinary, evidence of complementary and integrated expertise and appropriate resources
- quality of the research environment in which the work will take place
- potential impact on cancer control
- degree to which the proposed research addresses the Society’s strategic priorities to reduce cancer incidence, reduce cancer mortality, and improve the quality of life for Canadians living with and beyond cancer
Letter of Intent (LOI)
There is a limit of one Impact Grant application per Principal Investigator/Co-Principal Investigator in a competition, and only one can be held by a Principal Investigator/Co-Principal Investigator at any given time.
The LOI submission will require the following:
- an impact statement which addresses the potential of the project to exert a sustained, powerful influence on the research field(s) involved and how this work will reduce cancer incidence, reduce cancer mortality or improve patient quality of life. The statement should explicitly describe how the project will promote major advancement in cancer research which will accelerate and focus the knowledge gained from scientific findings, in the short or long term, into outcomes such as optimized patient care, improved treatment or reduced cancer burden
- a scientific abstract
- up to 3 pages of figures/tables/charts and associated legends
- a summary of the proposed research (maximum of 3 pages, single-spaced)
- a preliminary budget
- the names of the investigator(s) and CVs for the PI and any co-PIs
- the names of suggested reviewers/exclusions.
The summary of the proposed research should include the following:
- the specific research question to be addressed
- background and scientific rationale
- design and methodology
- relevance of the proposed research to this program
Impact Grants are not intended to support incremental scientific advances but to promote major advancement in research programs that will impact cancer, whether at the fundamental discovery stage or in more applied research.
Please note that changes to the applicant list or significant changes to the abstract after the LOI deadline are permitted, but must be provided to the CCS as they are determined.
When preparing the full application, the following will be required. Specific guidelines for the online application are available.
- as part of the public (non-scientific) summary, a cancer relevance statement clearly describing the potential of this project to impact cancer control
- a scientific abstract (the abstract can be updated from the LOI submission)
- an impact statement (this statement can be updated from the LOI submission). The statement should explicitly describe how the project will promote major advancement in cancer research which will accelerate and focus the knowledge gained from scientific findings, in the short or long term, into outcomes such as optimized patient care, improved treatment or reduced cancer burden.
- a detailed scientific proposal clearly stating the aims of the project including any previous work done in the area, experimental design, methods and analysis. Details of the investigator(s) including which member(s) of the research team will be responsible for which aspect of the project and a rationale for their inclusion in the project are required, as well as a description of the research environment where the work will take place. The proposal will contain no more than 10 pages of single spaced text. In addition, 5 pages of data figures/tables/charts plus 3 pages of supporting non-data schematics/flow diagrams (e.g. to depict signalling pathways, etc.) and their associated legends are allowed.
- a budget justification related to the supplies, equipment and personnel associated with the research project. This must include the number of personnel required to complete the work and a description of their experience and/or education level and their commitment to the project.
Multiple applications/multiple sources of funding
There must not be substantive overlap (more than 50%) with any pending application (including those at the abstract or Letter of Intent submission stage) to any other CCS Research program as of this competition due date. Duplicate applications will not be accepted. The onus is on the applicant to indicate the extent (or absence) of overlap. Grantees can accept funds from other sources, up to the CCS Research panel recommended amount.
Applicants are reminded to review the eligibility and requirements section for details on scientific and financial reporting, funder acknowledgement, Canadian Cancer Society policies on open access and tobacco related funding.
Last modified on: November 21, 2017